Afficher la notice abrégée

Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort

dc.rights.licenseopenen_US
dc.contributor.authorGRINDA, T.
dc.contributor.authorANTOINE, A.
dc.contributor.authorJACOT, W.
dc.contributor.authorBLAYE, C.
dc.contributor.authorCOTTU, P. H.
dc.contributor.authorDIÉRAS, V.
dc.contributor.authorDALENC, F.
dc.contributor.authorGONCALVES, A.
dc.contributor.authorDEBLED, M.
dc.contributor.authorPATSOURIS, A.
dc.contributor.authorMOURET-REYNIER, M. A.
dc.contributor.authorMAILLIEZ, A.
dc.contributor.authorCLATOT, F.
dc.contributor.authorLEVY, C.
dc.contributor.authorFERRERO, J. M.
dc.contributor.authorDESMOULINS, I.
dc.contributor.authorUWER, L.
dc.contributor.authorPETIT, T.
dc.contributor.authorJOUANNAUD, C.
dc.contributor.authorLACROIX-TRIKI, M.
dc.contributor.authorDELUCHE, E.
dc.contributor.authorROBAIN, M.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorCOURTINARD, Coralie
dc.contributor.authorBACHELOT, T.
dc.contributor.authorBRAIN, E.
dc.contributor.authorPEROL, D.
dc.contributor.authorDELALOGE, S.
dc.date.accessioned2021-06-29T08:04:44Z
dc.date.available2021-06-29T08:04:44Z
dc.date.issued2021-04-23
dc.identifier.issn2059-7029en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/79310
dc.description.abstractEnBACKGROUND: Treatment strategies for metastatic breast cancer (MBC) have made great strides over the past 10 years. Real-world data allow us to evaluate the actual benefit of new treatments. ESME (Epidemio-Strategy-Medico-Economical)-MBC, a nationwide observational cohort (NCT03275311), gathers data of all consecutive MBC patients who initiated their treatment in 18 French Cancer Centres since 2008. PATIENTS AND METHODS: We evaluated overall survival (OS) in the whole cohort (N = 20 446) and among subtypes: hormone receptor positive, human epidermal growth factor 2 negative (HR+/HER2-; N = 13 590), HER2+ (N = 3919), and triple-negative breast cancer (TNBC; N = 2937). We performed multivariable analyses including year of MBC diagnosis as one of the covariates, to assess the potential OS improvement over time, and we described exposure to newly released drugs at any time during MBC history by year of diagnosis (YOD). RESULTS: The median follow-up of the whole cohort was 65.5 months (95% CI 64.6-66.7). Year of metastatic diagnosis appears as a strong independent prognostic factor for OS [Year 2016 HR 0.89 (95% CI 0.82-0.97); P = 0.009, using 2008 as reference]. This effect is driven by the HER2+ subcohort, where it is dramatic [Year 2016 HR 0.52 (95% CI 0.42-0.66); P < 0.001, using 2008 as reference]. YOD had, however, no sustained impact on OS among patients with TNBC [Year 2016 HR 0.93 (95% CI 0.77-1.11); P = 0.41, using 2008 as reference] nor among those with HR+/HER2- MBC [Year 2016 HR 1.02 (95% CI 0.91-1.13); P = 0.41, using 2008 as reference]. While exposure to newly released anti-HER2 therapies appeared very high (e.g. >70% of patients received pertuzumab from 2016 onwards), use of everolimus or eribulin was recorded in less than one-third of HR+/HER2- and TNBC cohorts, respectively, whatever YOD. CONCLUSION: OS has dramatically improved among HER2+ MBC patients, probably in association with the release of several major HER2-directed therapies, whose penetrance was high. This trend was not observed in the other subtypes, but the impact of CDK4/6 inhibitors cannot yet be assessed.
dc.language.isoENen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subject.enMetastatic breast cancer
dc.subject.enReal-life
dc.subject.enOverall survival
dc.subject.enHER2
dc.subject.enNew drugs
dc.title.enEvolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.esmoop.2021.100114en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed33895695en_US
bordeaux.journalESMO Openen_US
bordeaux.page100114en_US
bordeaux.volume6en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue3en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamEPICENEen_US
bordeaux.teamEPICENE_BPH
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03273275
hal.version1
hal.date.transferred2021-06-29T08:04:50Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=ESMO%20Open&amp;rft.date=2021-04-23&amp;rft.volume=6&amp;rft.issue=3&amp;rft.spage=100114&amp;rft.epage=100114&amp;rft.eissn=2059-7029&amp;rft.issn=2059-7029&amp;rft.au=GRINDA,%20T.&amp;ANTOINE,%20A.&amp;JACOT,%20W.&amp;BLAYE,%20C.&amp;COTTU,%20P.%20H.&amp;rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
BPH_ESMOO_2021_Grinda.pdf
Taille:
974.9Ko
Format:
PDF
Voir/Ouvrir
Thumbnail
Nom:
license_rdf
Taille:
811octets
Format:
application/rdf+xml
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée